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Bacteriophage displayThe Hepatitis B virus precore protein is processed in the endoplasmic reticulum (ER) into secreted hepatitis
B e antigen (HBeAg), which acts as an immune tolerogen to establish chronic infection. Downregulation of
secreted HBeAg should improve clinical outcome, as patients who effectively respond to current treatments
(IFN-α) have signiﬁcantly lower serum HBeAg levels. Here, we describe a novel reagent, a single variable
domain (VNAR) of the shark immunoglobulin new antigen receptor (IgNAR) antibodies. VNARs possess
advantages in stability, size (~14 kDa) and cryptic epitope recognition compared to conventional antibodies.
The VNAR domain displayed biologically useful afﬁnity for recombinant and native HBeAg, and recognised a
unique conformational epitope. To assess therapeutic potential in targeting intracellular precore protein to
reduce secreted HBeAg, the VNAR was engineered for ER-targeted in vitro delivery to function as an
intracellular antibody (intrabody). In vitro data from HBV/precore hepatocyte cell lines demonstrated
effective intrabody regulation of precore/HBeAg.boratory, 41 Victoria Parade,
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Hepatitis B virus (HBV) affects more than 350 million people
globally and is a major health concern causing acute and chronic liver
disease, leading to hepatocellular carcinoma and cirrhosis (Kane,
1996; Lavanchy, 2004). Chronic hepatitis B (CHB) is the 10th leading
cause of death worldwide (Lavanchy, 2004). The precore or hepatitis
B e antigen (HBeAg) and core or HBcAg are encoded by the precore-
core (preC-C) gene, and are transcribed from separate, although
highly homologous, RNA transcripts. Accordingly, the two proteins
share signiﬁcant amino acid identity (Fig. 1), although likely structural
differences between these proteins, due to the 10 unique residues at
the HBeAg N-terminus, may also mediate antigenic variation (Revill et
al., 2010). The mature intracellular HBcAg protein (p21) of 183
residues (~21 kDa) includes an arginine-rich DNA binding protamine
domain at the C-terminus, and forms the viral nucleocapsid. Theprecore precursor protein (p25) is processed into the HBeAg as
follows. A 29-residue signal peptide at the N-terminus directs the
precursor protein to the endoplasmic reticulum for two-step proces-
sing. Initially, the 19 N-terminal residues are cleaved (Dienes et al.,
1995) to produce an intracellular intermediate (p22). Next, the 34
residues encoding the arginine-rich protamine domain are cleaved
from the C-terminus by a furin-like protease (Messageot et al., 2003;
Takahashi et al., 1983) to produce the HBeAg protein (p17), which is a
secreted protein of 159 residues (~17 kDa) (Milich et al., 1998).
Functionally, the role of HBeAg in the viral life cycle is poorly
understood (Chen et al., 2003). The HBeAg is a secreted accessory
protein, which appears to attenuate the host immune response to the
intracellular nucleocapsid protein (Chang et al., 1987; Chen et al.,
2004). The HBeAg acts as an immune tolerogen contributing to HBV
persistence (Chen et al., 2005), and possibly functions in utero
considering that soluble HBeAg traverses the placenta (Milich et al.,
1990). Furthermore, HBeAg downregulates: i) cellular genes control-
ling intracellular signaling (Locarnini et al., 2005); and ii) the Toll-like
receptor 2 (TLR-2) to dampen the innate immune response to viral
infection (Riordan et al., 2006; Visvanathan et al., 2007). In the
absence of HBeAg, HBV replication is associated with upregulation of
the TLR2 pathway (Visvanathan et al., 2007). Taken together, the
reported data suggest that HBeAg has a signiﬁcant role in modulating
virus/host interactions to inﬂuence the host immune response.
Fig. 1. Processing and comparative alignment of HBeAg and HBcAg (genotype D). (A) the precore precursor protein (p25) is processed N- and C-terminally to produce the HBeAg
(p17) of 159 residues (~18 kDa), numbered −10 to 149. The 10 N-terminal signal sequence residues are unique to HBeAg. The HBcAg (p21), produced from a separate RNA
transcript, consists of 183 residues (~21 kDa) numbered 1–183, and has 34 unique residues at the C-terminus. The HBeAg and HBcAg share a common core domain of 149 residues.
(B) sequence alignment of p25, p17 and p21 proteins, highlighting the 10 N-terminal unique residues of p17 (bold), the 19mer N-terminal ER signal sequence of p25 precursor
(underlined), and the 34 C-terminal residues speciﬁc for p21 (italicised).
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secretion could exert a potential antiviral effect, and may be of future
clinical relevance.
The immunoglobulin new antigen receptor (IgNAR) is a unique
antibody isotype found in cartilaginous ﬁsh (sharks and possibly
rays), and both immune and naïve molecular libraries of IgNAR
variable domains have been constructed and screened to isolate
binding reagents (Greenberg et al., 1995; Nuttall et al., 2001). IgNAR's
are bivalent, but target antigen through a single immunoglobulin
variable domain (~14 kDa) displaying two complementarity deter-
mining region (CDR) loops attached to varying numbers of constant
domains (Nuttall et al., 2003; Roux et al., 1998). In contrast, traditional
immunoglobulin (Ig) antibodies have a variable heavy (VH)+variable
light (VL) domain format (~26 kDa) and bind antigen through up to
six CDRs (Chothia et al., 1989; Padlan, 1994). The small size and
thermodynamic and chemical stability (Nuttall et al., 2004) of IgNAR
variable domains (VNARs) offer distinct advantages over conventional
antibodies. Furthermore, VNAR domains access cryptic antigenic
epitopes through unusually long and variable CDR3 loops (Nuttall
et al., 2004; Stanﬁeld et al., 2004; Streltsov et al., 2004, 2005). These
novel VNAR qualities make them an attractive immunoglobulin
scaffold to be developed for targeted intracellular antibody (intra-
body) delivery in vitro, and subsequent development as an in vivo
immunoglobulin therapy. Intrabodies utilising alternative scaffolds
have previously been reported targeting several other viral proteins
(reviewed in Nuttall andWalsh, 2008), including the HBV surface and
core antigens (Serruys et al., 2009, 2010).
Here, we describe the isolation, characterisation and development
of a VNAR domain targeting HBeAg as an anti-HBe intrabody. We
analyse speciﬁcity, binding kinetics, and epitope recognition to
demonstrate the VNAR utility in target antigen recognition. Further-
more, we assess future therapeutic potential of the anti-HBe VNAR
through investigation of the in vitro effects on intracellular andextracellular precore/HBeAg regulation, following development of the
VNAR as an endoplasmic reticulum (ER) localised intrabody.
Results
Isolation and characterisation of HBV HBeAg/HBcAg speciﬁc VNAR
To identify novel single-domain binding reagents against recom-
binant HBeAg target antigen, we screened a naive VNAR display
bacteriophage library (Nuttall et al., 2003). Variability focused on the
long VNAR CDR3 loop (15–18 residues), and to a lesser extent within
the CDR1 and framework regions (Nuttall et al., 2003). An increase in
eluted bacteriophage titre (~100-fold) was observed between biopan-
ning rounds 3 and 4 (data not shown), with 100% of colonies positive
for VNAR sequences by colony PCR (data not shown), indicating
positive selection. ELISA analysis of the isolated VNAR's using HBeAg
identiﬁed a group of similar clones that showedmarked binding above
background, and upon further analysis, all could be classiﬁed into one
of two sequence types, differing at only 4 residues. Of these, the clones
designated H6 and H3, represent the two identiﬁed sequence types.
The deduced amino acid sequences of VNAR clones H6 and H3 are
presented in Fig. 2A, and further incorporate in-framedual octapeptide
FLAG epitope tags and two alanine linker regions at the C-terminus.
These sequences revealed typical VNAR domains of 113 residues, with
large (18 residue) CDR3 loops and an invariant disulphide bridge
(Cys22–Cys83) connecting the two β-sheets, typical of the immuno-
globulin fold (illustrated in Fig. 2B). Two further cysteine residues
present within the CDR1 and CDR3 loop regions (Cys29 and Cys95) are
consistent with formation of an interloop disulphide bridge (Streltsov
et al., 2005). Dominant selection of just two clones after four rounds of
biopanning represents a high enrichment factor (N108). Such positive
selectionmay be due to high afﬁnity for the target antigen, and/or by a
competitive advantage provided by superior expression qualities of
Fig. 2. Identiﬁcation of HBeAg/HBcAg speciﬁc VNARs. (A) alignment of the amino acid sequences of the two isolated VNARs, H6 and H3 (Accession numbers EU213060 and EU213061).
The four dissimilar residues are indicated in bold and underlined. The CDR1 and CDR3 regions are boxed and shaded for identiﬁcation. Also included is the non-speciﬁc library clone
control VNAR (Ct) sequence. (B) A ‘typical’ VNAR, in this case the 12A-9 clone (PDB: 2COQ [47]), illustrating the canonical (22–83) and inter-CDR (CDR1–CDR3; 29–89) disulphide
bridges. Note the absence of a CDR2 loop region. (C) SEC elution proﬁle of afﬁnity-puriﬁed H6 VNAR protein. The peak eluting at 29 min is consistent with a monomeric domain
(theoretical molecular mass 14.7 kDa). The absorbance at A280nm is given in arbitrary units. Standard molecular masses in kDa are indicated. The inset in shows the VNAR H6 sample
analysed by SDS-PAGE (10%). (D) Comparative ELISA analysis of the binding speciﬁcity of VNAR H6 with non-speciﬁc control VNAR domain for immobilised HBeAg and HBcAg puriﬁed
target antigens, and for GST and lysozyme (negative control proteins). Data represent the average of triplicate wells and are normalised to PBS background. (E) Analysis of VNAR H6
afﬁnity by ELISA for in vitro expressed HBeAg/HBcAg. Puriﬁed H6 VNAR coated to ELISA plate wells was tested for binding afﬁnity to p25 (HBeAg) and p21 (HBcAg) produced in
transiently transfected Huh-7 cells, localised to the cell lysate (lys) or exported into culture supernatant (sn). Empty vector (EV) was incorporated as a control. Data represent the
average of quadruplicate wells from duplicate experiments.
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framework CDR3 junction (residues 83–85), suggest that this family is
derived from the native shark repertoire (Dooley and Flajnik, 2006).
Expressed and puriﬁed VNAR eluted as single peak by size exclusion
chromatography (SEC) (Fig. 2C), corresponding to a protein of
~14.7 kDa, consistent with the expected size of a monomeric VNAR
domain (Fig. 2C). TheH6 andH3protein expression characteristics and
size exclusion chromatography proﬁles were almost identical,
emphasising the similarity of the two proteins.
Based on superior target antigen recognition and the anti-HBe
speciﬁcity of VNAR H6 demonstrated by ELISA (Fig. 2D), the H6 VNAR
was selected for further study. The H6 VNAR recombinant proteindisplayed strong recognition for HBeAg (A405nm 1.94±0.1), and
exhibited weak cross-reaction for truncated HBcAg (A405nm 0.52±
0.04) (Fig. 2D), both of which are a mix of dimer and capsid protein
format by SEC (data not shown). This indicates that the VNAR binding
site lies within the 149 residues that are common to both HBeAg and
HBcAg (Fig. 1), but that theHBeAg is dominantly recognised, likely due
to slight variations in the structural conformation of HBeAg compared
with HBcAg (truncated) mediated by the unique N-terminal 10
residues (Revill et al., 2010). Non-speciﬁc afﬁnity was not observed
to the control antigens (GST or lysozyme). Furthermore, non-speciﬁc
VNAR binding to HBeAg or HBcAg was not apparent as a control VNAR
domain (a non-speciﬁc library clone, Fig. 2A, Ct) failed to display any
Table 1
Binding afﬁnities of VNARs H6 and H3 for HBeAg and HBcAg target proteins.
Target
Ag
VNAR ka
(M−1 s−1)
kd
(s−1)
Kinetic
KD (nM)
Equilibrium
KD (nM)
Overall
KD (nM)
HBeAg H6 1.3±0.2×106 6.1±0.3×10−2 49±3.8 57 53±5.7
H3 8.6±0.9×105 8.8±1.7×10−2 101 110 106±6.6
HBcAg H6 1.5±0.2×106 10.8±0.6×10−2 74 105 90±22
H3 1.0±0.9×105 14.0±1.1×10−2 140 152 146±8.7
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respectively, Fig. 2D). The H6 VNAR displayed reactivity to precore
(p25) antigen expressed in Huh7 lysates (Fig. 2E), although reactivity
to in vitro produced core (p21) protein was not apparent, suggesting
H6 VNAR is speciﬁc for in vitro precore protein.
VNAR binding afﬁnity analysis
To determine the H6 VNAR binding kinetics, HBeAg or HBcAg GST-
tag fusion proteins were captured to an α-GST surface for surface
Plasmon resonance (SPR) measurements using a Biacore T100
(Fig. 3A). This conﬁguration correctly orientated the HBeAg and
HBcAg on the chip for measuring (in triplicate) the binding
interactions with the VNAR domain analytes. Consistent with the
ELISA ﬁndings, the H6 (and H3) VNAR displayed binding recognition
for (SEC puriﬁed) recombinant HBeAg and HBcAg target proteins
(Figs. 3B, C), and furthermore the H6 VNAR target antigen binding was
again superior to the H3 clone (Table 1). There was no binding of the
H6 monomer to a blank surface (data not shown). The bindingFig. 3. Binding interactions of H6 VNAR with HBeAg and HBcAg target antigens.
(A) overview of Biacore SPR experiments, illustrating α-GST and HB(e/c)Ag-GST
binding surface baselines for analysis of VNAR binding kinetics. (B–C) overlaid Biacore
sensorgrams showing the interaction between HBeAg or HBcAg, and peak-puriﬁed
monomeric H6 VNAR (ranging from 26.25 to 420 nM) analyte. The HBeAg-GST or
HBcAg-GST fusion protein was captured by binding to an immobilised mouse anti-GST
antibody; VNAR analyte binding was measured in HBS buffer at a constant ﬂow rate of
30 μl/min with an injection volume of 90 μL. Data were averaged from triplicate
experiments (B) Binding afﬁnity interactions of captured HBeAg-GST with VNAR H6
analyte; (C) Binding afﬁnity interactions of captured HBcAg-GST with VNAR H6 analyte.reaction pattern indicated rapid association of VNAR H6 with HBeAg
and HBcAg to reach reaction equilibrium, which was followed by
rapid dissociation (Figs. 3B, C). The rapid realisation of reaction
equilibrium allowed for determination of binding parameters using
both kinetic and equilibrium analysis methods. The various binding
afﬁnities and reaction rates are summarised in Table 1. Signiﬁcant
observations include: (i) the highest afﬁnity (53 nM)was between H6
and HBeAg (Fig. 3B); and (ii) the afﬁnity (90 nM) between H6 and
HBcAg (truncated) was 1.7-fold weaker (Fig. 3C). The H6 binding data
consistently indicated an increased afﬁnity for HBeAg compared to
HBcAg (truncated); therefore we hypothesise that the binding
epitope is better displayed by HBeAg due to minor structural
variations in protein folding inﬂuenced by the 10 unique residues at
the N-terminus (Revill et al., 2010). Determination of the epitope
binding sitemay ultimately require the co-crystallisation resolution of
the HBeAg-H6 VNAR and/or HBcAg-H6 VNAR binding complexes, which
could also facilitate further maturation of the H6 VNAR to improve
HBeAg afﬁnity and speciﬁcity, through targeted structural manipula-
tion of the CDR3 loop residues.
Immunoassay epitope mapping of VNAR H6
We hypothesised that the H6 VNAR recognises a conformational
epitope, based on previous IgNAR publications that suggest the
extended VNAR CDR3 loop enables access to cryptic antigen pockets
(Nuttall et al., 2004; Stanﬁeld et al., 2004; Streltsov et al., 2004, 2005).
Binding recognition of H6 VNAR to HBeAg was not affected in
competitive ELISA binding with several conventional anti-HBe/HBc
antibodies (data not shown), which suggested the H6 VNAR recognizes
an alternative and non-proximally obscured HBeAg epitope to the
tested anti10 HBe/c antibodies. Peptide library mapping of the H6
VNAR using overlapping linear HBeAg epitopes (residues -10 to 149)
further conﬁrmed that the H6 VNAR recognises a conformational
epitope (data not shown). The H6 VNAR displayed no speciﬁc
recognition for any of the HBeAg peptides, and neither did the control
VNAR, although a strong binding response was elicited to full-length
recombinant HBeAg.
Immunoassay epitope mapping of VNAR H6
We hypothesised that the H6 VNAR recognises a conformational
epitope, based on previous IgNAR publications that suggest the
extended VNAR CDR3 loop enables access to cryptic antigen pockets
(Nuttall et al., 2004; Stanﬁeld et al., 2004; Streltsov et al., 2004, 2005).
Binding recognition of H6 VNAR to HBeAg was not affected in
competitive ELISA binding with several conventional anti-HBe/HBc
antibodies (data not shown), which suggested the H6 VNAR recognizes
an alternative and non-proximally obscured HBeAg epitope to the
tested anti10 HBe/c antibodies. Peptide library mapping of the H6
VNAR using overlapping linear HBeAg epitopes (residues -10 to 149)
further conﬁrmed that the H6 VNAR recognises a conformational
epitope (data not shown). The H6 VNAR displayed no speciﬁc
recognition for any of the HBeAg peptides, and neither did the control
VNAR, although a strong binding response was elicited to full-length
recombinant HBeAg.
Fig. 4. Construction and expression of H6 Intrabody. (A) diagram illustrating the
intrabody expression cassette in pShooter pCMV/ER vector. The H6 VNAR or control VNAR
sequences with dual C-terminal FLAG tags were inserted into BssHII/XhoI restriction
sites, in frame with an N-terminal ER signal sequence and a C-terminal ER retention
sequence. (B) expression of H6 (IntB) and control intrabody (ct IntB) in comparison to
empty vector (EV), transfected into Huh7 pTRE precore and core stable expression cell
lines was conﬁrmed by WB using anti-FLAG antibody detection. The H6 intrabody
(IntB) displayed products with pre- and post-ER signal sequence cleavage.
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The precore precursor protein (p25) is localised to the ER via an ER
signal sequence, and processed prior to export as the p17 HBeAg
(Chen et al., 2008; Ito et al., 2009). To bind precore protein and inhibit
secretion, H6 VNAR intrabody expression was localised to the ER by
cloning into the pCMV/ER plasmid, which incorporated an N-terminal
ER signal sequence (cleaved upon ER localisation) and a C-terminal ER
retention motif to prohibit intrabody and bound target protein
secretion (Fig. 4A). Western Blotting (WB) analysis of precore- and
core-expressing pTRE cell lines transfected with intrabody (IntB),
control intrabody (ct IntB) or empty vector (EV), demonstrated
effective intrabody expression (Fig. 4B). The H6 intrabody was
detected in both cell lines as a doublet band, representing pre- and
post-ER signal sequence cleavage. The ct IntB was not as effectively
processed for signal sequence removal.
Intrabody effect on HBV precore protein in vitro
To investigate the intrabody effect on precore protein, the
intrabody (IntB) construct (and control intrabody, ct IntB; and
empty vector, EV) was transfected into precore, core and control
pTRE cell lines, which stably express the speciﬁed HBV (genotype D)Fig. 5. Analysis of intrabody effect on HBeAg expression in vitro. WB analysis (upper) of HBe
HepG2.2.15 HBV-expressing cell lines (B), transfected with H6 intrabody (IntB), control in
extracellular supernatant (sn). Blots were probed with anti-HBe/c, anti-HBe (AD38 and
expression, and also with anti-Tubulin (Tub) for total cell lysate loading control. Densitometr
proteins in lys and sn (pTRE cell lines only as AD38 and HepG2.2.15 cell lines secretion comproteins, and also into AD38 and HepG2.2.15 HBV-expressing
(genotype D) cell lines. Cell lysates (lys) and supernatants (sn)
were analysed by WB (Fig. 5) and quantitative HBeAg Architect assay
(Fig. 6). WB data and subsequent densitometry analysis (Fig. 5)
suggested intrabody (IntB) treatment regulated precore/HBeAg (p25
and p17) in comparison to control intrabody (ct IntB) and empty
vector (EV) controls. Intrabody (IntB) treatment of pTRE precore cells
(Fig. 5A) demonstrated a decrease in intracellular p25 levels (0.9
fold), possibly indicating an increase in ER degradation, coupled with
a dramatic reduction of secreted p17 HBeAg (0.3 fold). These data
strongly suggested that the intrabody is capable of disrupting precore
processing and reducing p17 secretion. The core protein (p21) was
unaffected by intrabody treatment, either due to a failure of intrabody
to recognise p21 core in vitro (suggested in Fig. 2E), or due to a
differential subcellular localisation of intrabody in the ER, and the p21
core localised to the cytosol. The AD38 cells (Fig. 5B), which are HBeAg
secretion incompetent and virion secretion impaired, displayed a very
minor (1.1–1.2 fold) increase of intracellular p25 with intrabody
treatment, and no signiﬁcant effect on intracellular p17 levels (0.9–1.1
fold). The intrabody transfected HepG2.2.15 cells (Fig. 5B), which
exhibit partially impaired secretion, showed both reduced intracellu-
lar p25 (0.6–0.8 fold) and signiﬁcantly reduced secreted p17 HBeAg
(0.5 fold), similar to the response observed in pTRE precore cells. This
further supported precore/HBeAg regulation and reduced secretion
with in vitro intrabody treatment.
Analysis of intrabody treatment of the pTRE precore and core, and
the AD38 cell lines by quantitative HBeAg Architect assay (Fig. 6)
supported the WB data. Intrabody (IntB) treatment had no recogni-
sable effect on p21 core protein (Fig. 6B), as expected, however p17
was reduced in pTRE precore (Fig. 6A) supernatant (0.7 fold) similar
to the WB response. In the secretion incompetent AD38 cell lysates
(Fig. 6C) p25/p17 increased (1.4 fold), which was suggestive of ER
accumulation and interference with precore processing.
The effects of intrabody treatment on pTRE cell lines (precore, core
and control) were examined using triple label immunostaining for
confocal microscopy (Fig. 7). Cells were antibody stained for anti-HBe/c
(magenta) expression, intrabody (green) expression (FLAG tag), and
the ER (red) subcellular compartment (PDI), in order to investigate
co-localisation and intrabody effect on precore protein. Overlay of the
anti-HBe and IntB staining indicated co-localisation (white area) of the
intrabody and precore protein (pTRE precore cells). Furthermore, triple
staining overlays indicated localisation to the ER (white area). Co-
localisation was not observed in pTRE core or control cells, or with
control intrabody transfection. Most interesting was that precore
protein staining appeared to be modiﬁed when co-localised in the
cells with transfected anti-HBe intrabody. Staining patterns changed
from punctate to ubiquitous in appearance (Fig. 7, pTRE precore cells),
possibly suggesting intrabody treatment inhibited some level of
intracellular precore aggregation. This modiﬁcation to intracellular
precore protein could translate into increased ER degradation to reduce
p17 HBeAg secretion. Decreased precore aggregationmay also improve
p25 detection by WB and architect assay techniques, through allowing
improved epitope accessibility for detection.
Discussion
This study describes the characterisation and in vitro intrabody
application of an isolated VNAR single domain antibody targeting the
HBeAg of HBV. Screening of an in vitro naïve bacteriophage-displayed
library of VNAR domains, containing both synthetic and natural CDR3Ag regulation in Huh7 pTRE precore, core or control stable cells lines (A), or AD38 and
trabody (ct IntB) or empty vector (EV). Cells were harvested for cell lysate (lys) and
HepG2.2.15 only to discriminate between p25/17 and p21), anti-FLAG for intrabody
y (lower) was performed on the detected precore/HBeAg (p25 and p17) and core (p21)
promised), which was reported as fold change. nt designates not tested.
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Fig. 6. Quantitative Architect assay analysis (PE IU/mL) of precore (p25 and p17) and
core (p21) antigen levels in cell lysates and supernatants following in vitro intrabody
transfection. (A) Huh7 pTRE precore cells transfected with H6 intrabody (IntB) versus
control intrabody (ct IntB) and empty vector (EV), or non-expressing control pTRE cells.
(B) as for (A) except using Huh7 pTRE core cells. (C) as for (A) except using AD38 HBV
infectious cells, which are secretion incompetent.
Fig. 7. Confocal immunostaining analysis of Huh7 pTRE precore, core and control cell
lines transfected (Tf) with anti-HBe intrabody versus control intrabody. Transfected
cells were triple stained with 1D8 anti-HBe/c conjugated to AlexaFluor647 (magenta),
anti-FLAG FITC (green) for intrabody, and rabbit anti-PDI with anti-rabbit Texas Red
secondary (red) for ER localisation. Overlays of double and triple staining display
regions of co-localisation (white).
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H6 and H3. This selection process mirrors the antigen-driven
selection/proliferation/maturation process seen in the natural shark
immune system. Perhaps not surprisingly, given the close homology
(149 common residues) between HBeAg and HBcAg, which are
transcribed from a shared ORF, there was low level cross-reactivity by
both VNARs to recombinant HBcAg (truncated), although HBeAg was
dominantly recognised. There was, however, no afﬁnity displayed for
in vitro p21 core, which is likely due to additional protein processing/
folding in eukaryotic cells. Although it is uncertain how structurally
related these two HBV proteins are, the cross-reactivity observed here
varied by approximately 2-fold afﬁnity, which is indicative of minor
variations in protein conformation subtly altering the antibody-
binding site. The isolated VNARs, H6 and H3, shared close homology,
differing at only 4 residues (one in the CDR1 loop), but were
signiﬁcantly different from other VNARs selected from this library in
both their framework and CDR sequences, with a long CDR3 loop (18
residues) biased toward bulky hydrophobic residues. Despite differing
at only 4 residues, H6 had a 2-fold increase in binding afﬁnity
compared with H3 for HBeAg. The difference between the two VNARsrelates to their sequence variation, which occurred most signiﬁcantly
in the CDR1 loop (Ser33/Gly33) but also in the top of heavy loop 4
(residues Asn60/Ser60 and Thr62/Gly62), a region increasingly recog-
nised as important in the VNAR-antigen interaction (Dooley et al., 2006;
Kopsidas et al., 2006). Based on superior recognition of the target
antigen, VNAR H6 was selected for further investigation. Validation of
the H6 VNAR determined a high degree of afﬁnity and speciﬁcity for
recombinant HBeAg (overall KD of 53 nM) and HBcAg (90 nM), which
is comparable with afﬁnities reported for camelid VHH domains
(Muyldermans and Lauwereys, 1999) and for scFv and disulphide
stabilised Fv fragments (Reiter et al., 1996). The afﬁnity of the VNAR H6
for HBeAg and HBcAg exhibited a rapid association rate, a feature of
VNAR antibodies (SN, unpublished data). Thismay be due to the rigidity
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tion, followed by adoption of an induced ﬁt type conﬁguration
(Stanﬁeld et al., 2007) contributing to high afﬁnity binding.
The ability of the VNAR extended CDR3 loop to bind cryptic antigen
pockets suggests a conformational recognition epitope. Many con-
ventional anti-HBe/HBc (cross-reactive) antibodies target a common
linear epitope, the immunodominant loop (residues 74–83) located at
the α-helical spike of dimerised capsid subunit (Steven et al., 2005).
We hypothesised that the VNAR H6 domain recognises an alternative
conformational target site of HBeAg/HBcAg, by virtue of the extended
CDR3 loop. Peptide ELISA analysis using HBeAg linear epitopes
supported this, with speciﬁc H6 VNAR afﬁnity absent. Resolution of
the H6 VNAR target epitope may depend on the co-crystal structure
determination of the HBeAg/H6 VNAR and/or HBcAg/H6 VNAR binding
complexes. Structural determination of the VNAR binding site would
further allow for structure based design of the VNAR to improve
binding afﬁnity.
We further developed theH6VNAR as an intrabodywith intracellular
ER localised delivery to target intracellular precore protein, and an ER
retention signal to interfere with boundHBeAg secretion, thus reducing
extracellular HBeAg load. Intrabody transfection of precore- or core-
expressing pTRE cell lines (genotype D), or HBV-expressing (genotype
D) cell line (HepG2.2.15), showed a common trend for a considerable
downregulation of secreted p17 HBeAg, and downregulation of p25
intracellular precore, the scale of which was cell line dependant,
potentially due to cell line background differences. Importantly, despite
signiﬁcant sequence homology and cross-reactivity to recombinant
HBcAg (truncated), there was no intrabody regulation of p21 core in
vitro. This was likely due to different structural folding/epitope display
between precore and core protein in vitro, or due to limited ER localised
intrabody access to the cytoplasmic core antigen. In addition, the
intrabody interfered with intracellular precore processing/folding.
In vitro transfection and co-localisation of intrabody and precore to
the ER, which was demonstrated with confocal immunostaining
analysis, altered precore staining from the typical punctate/aggregated
state to a ubiquitous appearance. This suggests intrabody inhibits
precore aggregation or promotes ER degradation/processing of precore
to circumvent aggregation, and indicates that an anti-HBe VNAR may
possess therapeutic potential.
Immunoglobulins play an integral role in mediating and modulat-
ing the immune system, and research interests have increased to
develop immunoglobulins as novel therapeutics and diagnostics
(Nuttall and Walsh, 2008). The VNAR capabilities make them suitable
as protein reagents for diagnostic biosensor or proteomics applica-
tions, and furthermore, for development as immunoglobulin therapies
(Wesolowski et al., 2009). Indeed, there is precedence for the
treatment of HBV by immunoglobulin therapy (HBIg) (Schilling
et al., 2003), and more speciﬁcally, downregulation of the innate
response (TNF production) by HBeAg has been shown to be blocked in
vitro by treatment with anti-HBe polyclonal antibody (Visvanathan
et al., 2007). Engineering immunoglobulin domains (including VNAR's)
as intrabodies may offer several therapeutic applications through
inhibiting target protein interactions or function, promoting degrada-
tion or cell death, or disruption of subcellular localisation. Therapies
under development target: tumour antigens; infectious diseases (e.g.
HIV Tat protein [Bai et al., 2003] or HBV surface and core antigens
[Serruys et al., 2009, 2010]); transplantation; protein mutation-
associated diseases (e.g. prion proteins [Cardinale et al., 2005]); and,
protein aggregation diseases (Alzheimer's [Lynch et al., 2008]). To
circumvent present intrabody therapy issues related to in vivo gene
delivery, the intrabody in vitro validated anti-HBe VNAR, could be
engineered as a humanized antibody for in vivo immunoglobulin
therapy.
In this study we have utilised a VNAR molecular library targeting
the HBeAg of HBV at mid-nanomolar range afﬁnities. VNAR molecules
offer distinct advantages of compact size, robust stability and crypticantigenic epitope access via unusually long and variable CDR3 loops
(Nuttall et al., 2004; Stanﬁeld et al., 2004; Streltsov et al., 2004,
2005). Overall, this study presents an isolated VNAR domain targeting
HBeAg which has been further developed for intrabody activity
in vitro to establish effective regulation of intracellular precore,
alteration of precore processing/folding intracellularly, and reduction
of extracellular HBeAg. Regulation of extracellular HBeAg is a
valuable therapeutic tool to improve treatment efﬁcacy, and avoid
CHB progression. HBeAg titres above ~200 PE IU/mL result in higher
treatment failure rates, with response to IFN treatment enhanced
with lower HBeAg titres (Fried et al., 2008). Treatment to reduce
HBeAg load prior to IFN-α therapy has potential to improve patient
IFN treatment outcome. Further research to develop this treatment
for in vivo study, such as engineering human Fc domains to create
chimeric antibodies for delivery, would be an important step in
assessing future therapeutic potential and the promotion of antiviral
effectiveness.
Materials and methods
Recombinant HBeAg protein expression and puriﬁcation
Full-length HBeAg and C-terminally truncated HBcAg (149 resi-
dues) from HBV genotype D (Delaney and Isom, 1998) were cloned
into pGEX-6–1 vector (GE Healthcare, Uppsala, Sweden), and protein
expressed in BL21(DE3) Escherichia coli (E. coli) cells (Novagen,
Madison, WI, USA). Soluble recombinant protein was puriﬁed on
glutathione Sepharose 4B beads (GEHealthcare). Fusion proteinswere
either competitively eluted from the glutathione Sepharose with
10 mM reduced glutathione (Roche, Indianapolis, IN, USA), or were
cleaved from the GST fusion tag (on the resin) using PreScission
protease (GE Healthcare). Puriﬁed recombinant protein was dialysed
into PBS or 10–50 mM Tris pH 7.0–7.5, concentrated and quality
assessed by SDS-PAGE, SEC and N-terminal protein sequencing.
VNAR library selection and protein expression
Constructionof theWobbegong(Orectolobusmaculatus)VNAR library
(~4.0×108 independent clones) has been described previously (Nuttall
et al., 2003). Phagemid particles carrying the VNAR-gene3 protein were
propagated and isolated by standard procedures (Galanis et al., 1997).
For biopanning of the phagemid library, recombinant HBeAg (1.25–
3.75 μg/ml in PBS) was coated on to Maxisorb Immunotubes at 4 °C
overnight, and panning undertaken as described previously (Nuttall et
al., 2003). Phagemid particles were eluted using 2% triethylamine and
neutralised by the addition of 1 M Tris pH 7.5. Four rounds of panning
were performed, with the stringency of selection increasing at each
round. Following ﬁnal selection, E. coli TG1 were infected with
phagemid particles and plasmids propagated. The VNAR cassette was
extracted as a NotI/SﬁI fragment and subcloned into pGC cloning/
expression vector (Coia et al., 1997), and clones sequenced (GenBank
database accession numbers EU213060 and EU213061) using BigDye
terminator sequencing kit (Applied Biosystems, USA). Recombinant
VNAR protein was expressed in E. coli as previously described (Nuttall
et al., 2001), and periplasmic fractions isolated (Minsky et al., 1986) and
either used as crude fractions, or recombinant protein puriﬁed using an
anti-FLAG antibody-Sepharose column, and eluted with Immunopure®
gentle elution buffer (GEB; Pierce, Rockford, IL, USA), dialysed into PBS
or 10 mM Tris pH 7.0–7.5, and concentrated. Protein purity was
analysed by SDS-PAGE and by SEC.
Biosensor binding analysis
SPR measurements were performed using a Biacore T100 biosensor
system (Biacore AB, Uppsala, Sweden). CM5 sensor chips, mouse anti-
GST IgG antibody (α-GST), and all buffers were sourced from GE
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buffer (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.05% surfactant
P-20, pH 7.4). An indirect binding assay was used to analyse the
interaction between VNAR analyte and HBeAg or HBcAg (Fig. 3A). A
standard coupling protocol (Biacore T100 control software version 1.1)
was employed to immobilise the α-GST antibody (30 μg/ml, 10 mM
sodium acetate pH 5.0) at ~4000 response units (RU) (Johnsson et al.,
1991) inﬂowcells 1 (reference surface) and2 (test surface). HBeAg-GST
or HBcAg-GST (20 μg/ml) were injected (30 μl/min) overα-GST surface
resulting in a capture of approximately 264.5±12.4 RU of recombinant
protein. VNAR preparations (26.25 to420 nM),were injected (30 μl/min)
serially over the α-GST/HBe/cAg-GST (Fig. 3A) and reference surfaces.
Association and dissociation phases were each monitored for 10 min.
The VNAR and antigen surfaceswere regeneratedwithin the dissociation
phase, and the HBeAg-GST or HBcAg-GST surfaces were regenerated
between each set of VNAR concentrationswith 10 mMglycine pH 2.2. To
determine the kinetic parameters of the interactions, each data set was
double-referenced and ﬁt globally to a 1:1 interaction model using
Biacore T100 evaluation software (version 1.1).
Antibodies
The following primary antibodies were utilised: mouse anti-FLAG
monoclonal antibody (mAb) (WEHI, Australia); mouse anti-HBe mAb
(Fitzgerald, Concord, MA, USA); 1D8 mouse anti-HBe/c (VIDRL); 7E9
mouse anti-HBe (VIDRL); mouse anti-Tubulin (Abcam, Cambridge,
UK); and rabbit anti-PDI (ER stain) (SantaCruz, Santa Cruz, CA, USA).
The following horseradish peroxidase (HRP)-conjugated secondary
antibodies were utilised: goat anti-mouse immunoglobulin (Ig)
(Pierce); goat anti-rabbit HRP IgG H+L (Biorad, Hercules, CA, USA);
rabbit anti-mouse IgG (Dako); and mouse anti-FLAG M2 IgG (Sigma,
St Louis, USA). The following secondary antibodies were utilised in
immunostaining: mouse anti-FLAG FITC conjugate (Sigma); and goat
anti-rabbit Texas red conjugate (Abcam).
VNAR characterisation ELISA
For ELISA assays, recombinant proteins (0.4 μg/well) in PBS were
coated onto Maxisorb Immuno-plates (Nunc, Germany). Between
each step plates were rinsed twice with PBS and once with PBS/0.05%
Tween20. Wells were blocked with PBS/5% skimmilk powder (Blotto)
for 1 h, before incubation with VNAR periplasmic fractions or
recombinant protein for 1 h. Primary antibody in PBS/5% Blotto was
added, followed by HRP conjugated secondary antibody (in PBS/5%
Blotto). Plates were developed using ABTS (2,2 azino di-(ethyl)
benzthiazoline sulphonic acid [Roche]), and absorbance read at
A405nm.
Cloning VNAR into eukaryotic pCMV/ER expression vector
The H6 and control VNAR sequences including a double C-terminal
FLAG tag were PCR ampliﬁed with BssHII (Roche) and XhoI (Roche)
restriction sites. Digested insertwas ligated into similarly cut pShooter
pCMV/ER expression plasmid (Invitrogen, Carlsbad, CA, USA), in frame
with an N-terminal ER signal sequence and a C-terminal ER retention
sequence (Fig. 4A), the former of which is cleaved from the VNAR
protein upon ER localisation.
Cells and transfections
The following cells lines were used in intrabody transfection
experiments: Tetracycline (Tet) responsive Huh7 pTRE genotype D
precore (p25), core (p21) and control (empty vector) stable cell lines
(Locarnini et al., 2005); AD38 (Tet responsive) and HepG2.2.15 cells,
which express HBV genotype D (Ladner et al., 1997; Sells et al., 1987).
Transfections of intrabody, control intrabody and empty vector wereperformed as described below. pTRE cells lines (maintained Tet off for
7 days) were transfected with 2.2 μg DNA and 9.1 μl Fugene (Roche)
per 60 mm dishes according to manufacturer' instructions. AD38
(maintained Tet off for 7 days) and HepG2.2.15 cells were transfected
with 13.5 μg DNA and 21.6 μl Fugene per 100 mm dish. Transfection
reactions were adjusted according to the surface area of the culture
vessel. Precore & core protein for ELISA was produced from Huh7 cells
(Nakabayashi et al., 1982) transfected with constructs of pCI precore
(p25), pCI core (p21) and pCI empty vector using 3.8 μg DNA and
9.1 μl Fugene per 60 mm dish.
Analysis of precore/HBeAg in intrabody transfected cells
Transfected cells were harvested for protein analysis of extracel-
lular supernatant (sn) and intracellular lysate (lys). Sn was pelleted at
3000 rpm 5 min 4 °C to remove cell debris. Cell lysates were harvested
in 800 μl cell lysis buffer (50 mM Tris pH 7.5, 1 mM EDTA, 150 mM
NaCl, 0.5% NP40) for 15 min at RT, and nuclear material removed by
centrifugation at 16,000×g 5 min. Cell lys and sn were analysed by
WB and quantitative HBeAg serological assay (Architect, Abbott,
Chicago, IL, USA) (Thompson et al., 2010). For WB, samples were
resolved on SDS-PAGE gels (12.5%) and transferred to nitrocellulose
(GE Healthcare) according to standard protocols. Proteins were
detected using the following antibodies: mouse 1D8 anti-HBe/c
HRP; mouse 7E9 anti-HBe and mouse anti-FLAG HRP; and mouse
anti-Tubulin and rabbit anti-mouse HRP. Blots were developed with
chemiluminescence as per manufacturer's protocol (Perkin Elmer,
Waltham, MA, USA), and stripped for reprobing as per manufacturer's
protocol (Abcam). Cell lys and sn were also analysed by HBeAg
serological assay (Architect), as per manufacturer's instructions, and
were run against PE IU/mL standardised HBeAg samples for
quantiﬁcation.
Immunostaining of intrabody transfected cells
Coverslips of transfected pTRE precore, core and control cells were
ﬁxed in 4% paraformaldehyde (PFA) for 20 min and permeablised in
0.5% TritonX-100 for 8 min. Coverslips were blocked in 1% BSA in PBS,
and stained with the following primary and secondary antibodies in
1% BSA in PBS: mouse 1D8 anti-HBe/c Alexaﬂuor647 conjugate;
mouse anti-FLAG FITC conjugate; rabbit anti-PDI (ER stain); and goat
anti-rabbit Texas red conjugate. Coverslips were mounted in
FluoroPrep (BioMerieux, France), and analysed using a laser scanning
spectral (Leica TCS SP2) confocal microscope (Leica Microsystems,
Germany) using Leica confocal software.
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